Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference22 articles.
1. Brixner D, Iskedjian M, Copley-Merriman K, Kamae I, O’Donnell J, Ramsey SD, et al., ISPOR Implementation Working Group. ISPOR vision 2020: a look to the future [ISPOR communication initiatives]. South Lawrenceville: ISPOR; 2012.
2. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med. 1997;45(4):535–44.
3. Walkom E, Robertson J, Newby D, Pillay T. The role of pharmacoeconomics in formulary decision making. Formulary. 2006;41:374–86.
4. Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, et al. Use of pharmacoeconomics information: report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health. 2003;6(4):407–16.
5. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health. 2001;4(3):225–50.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献